asxan.ai Agents Hub

Athletic Performance

Evidence Stack

Muscle protein synthesis · ergogenic aids · recovery

Evidence-first sports-nutrition stack — what the human-evidence record actually shows for the ingredients most associated with muscle protein synthesis, ergogenic performance, and recovery, including the honest small evidence base for yeast protein and the mixed astaxanthin performance trials. This is mechanism and evidence mapping, not medical advice. Discuss any performance supplementation with a qualified sports-medicine or nutrition professional. All PubMed identifiers are verified against PubMed before inclusion; cross-market regulatory claims appear verbatim per their authorising authority (FDA · EFSA · ANVISA · TGA).

Last reviewed · How we assess evidence →

Quick Summary

  • Protein at roughly 1.6 g/kg/day is the muscle-protein-synthesis (MPS) ceiling. Morton 2018 meta-analysis of 49 RCTs (n=1,863) reported an effective intake threshold of approximately 1.6 g/kg/day, above which the marginal gain in lean mass plateaus (PMID 28698222). For strength athletes, ranges of 1.6 to 2.2 g/kg/day are evidence-supported.
  • Leucine ~2.5 to 3.0 g per meal triggers mTORC1. Churchward-Venne 2014 (PMID 24284442) demonstrated that 25 g whey or 6.25 g whey + supplemental leucine to match leucine content both stimulated MPS — confirming leucine as the key trigger.
  • Whey's acute MPS advantage is real; chronic advantage is smaller than marketing suggests. Acute head-to-head (Tang 2009 PMID 19589961): whey > soy > casein. Chronic 9-month head-to-head (Volek 2013 PMID 24015719): whey +3.3 kg vs soy +1.8 kg lean mass — whey still wins, but DIAAS-matched plant blends close most of the gap when total intake meets 1.6 to 2.2 g/kg/day. See /ingredients/protein/ and whey protein.
  • Yeast protein's evidence base is honest-small, not zero. Cao 2024 INFOGEST + rat study (PMID 39303477) places PDCAAS near 1.00 and DIAAS estimate near 0.82 to 1.00; Van den Abbeele 2026 ex-vivo gut-microbiota study (PMID 41568030) showed non-inferior to whey and soy on barrier and SCFA endpoints. Direct human muscle-endpoint RCT in yeast protein is currently limited.
  • Astaxanthin fatigue and motor function show meta-analytic signal. Liu 2024 meta-analysis (PMID 38243785) of 11 RCTs (n=346) reported significant pooled effects on fatigue and motor function; specific exercise-performance trials are more mixed.
  • Creatine and BCAA are scientifically important — preliminary / emerging here. Creatine is broadly the most evidence-backed ergogenic in the sports-nutrition literature; the Hespel 2001 J Physiol RCT (PMID 11600695) is the named disuse-recovery signal.
  • β-Alanine is a well-defined ISSN-position-stand ergogenic for ~1 to 4 minute exercise. Trexler 2015 ISSN position stand (PMID 26175657) concluded that 4 to 6 g/day of β-alanine for at least 4 weeks meaningfully increases muscle carnosine, buffering intracellular pH and enhancing performance in high-intensity exercise lasting roughly 1 to 4 minutes. Paraesthesia is the most commonly reported side-effect; divided dosing or sustained-release formulations reduce it.
  • The protein + resistance-training combination is the primary lever; supplements are the marginal lever. Cermak 2012 meta-analysis (PMID 23134885, 22 RCTs, n=680, younger + older adults) and Cintineo 2018 review (PMID 30255023, Front Nutr) both anchor the framing: in protein-adequate diets at 1.6 to 2.2 g/kg/day combined with resistance training, supplemental ergogenic aids contribute marginal — not foundational — gains.

The Evidence Stack

The "evidence" column below describes the strength and direction of the outcome evidence in qualitative terms — well-established, robust, moderate/mixed, preliminary/emerging, or null/negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

Ingredient Athletic-performance evidence (qualitative) Key Trial / Meta-analysis asxan.ai page
Protein (whole-protein) Well-established for MPS, lean mass, and body composition at the ~1.6 g/kg/day threshold Morton 2018 PMID 28698222 (1.6 g/kg/day threshold meta); Churchward-Venne 2014 PMID 24284442 (leucine trigger); Macnaughton 2016 PMID 27511985 (20 vs 40 g whole-body) /ingredients/protein/
Whey Protein Well-established for acute MPS; robust but narrower chronic lean-mass advantage vs plant proteins Tang 2009 PMID 19589961 (acute MPS head-to-head); Volek 2013 PMID 24015719 (9-month chronic); Baer 2011 PMID 21677076 (23-week body composition) /ingredients/whey-protein/
Yeast Protein Preliminary / emerging — strong in-vitro PDCAAS/DIAAS; direct human muscle-endpoint RCT limited Cao 2024 PMID 39303477 (PDCAAS ~1.00); Qiao 2025 PMID 40934397 (INFOGEST); Van den Abbeele 2026 PMID 41568030 (gut barrier non-inferior) /ingredients/yeast-protein/
Astaxanthin Moderate / mixed — meta-analytic fatigue and motor-function signal; specific exercise-performance trials mixed Liu 2024 PMID 38243785 (fatigue/motor meta); Brown 2021 PMID 32660833 (cycling); Liu 2021 PMID 34110707 (elderly aerobic); Gonzalez 2024 PMID 39568140 (firefighter mixed) /ingredients/astaxanthin/
Creatine Preliminary / emerging here — broadly well-established in the wider sports-nutrition literature Hespel 2001 PMID 11600695 (oral creatine + disuse rehab) /ingredients/creatine/
BCAA Preliminary / emerging here — leucine triggers mTOR but whole-protein outperforms in practice Leucine drives mTOR signal; whole-protein superior in chronic outcome trials /ingredients/bcaa/
β-Alanine (cross-reference) Robust for ~1 to 4 minute high-intensity exercise per ISSN position stand; not a general performance enhancer Trexler 2015 ISSN position stand PMID 26175657 (4-6 g/day ≥4 wk increases muscle carnosine, buffers pH) cross-reference only
Protein + Resistance Training (framing anchor) Well-established — the foundational lean-mass and strength lever; supplements layer on top Cermak 2012 meta PMID 23134885 (22 RCTs, n=680, younger + older); Cintineo 2018 review PMID 30255023 (Front Nutr) protein supp + RT/endurance recovery see /ingredients/protein/

How It Works

Each ingredient engages athletic biology by a different route — whole protein and whey through leucine-driven mTORC1 activation, yeast protein through its amino-acid spectrum, astaxanthin as a mitochondrial-membrane antioxidant, creatine through phosphocreatine ATP resynthesis and disuse recovery, and β-alanine through muscle-carnosine pH buffering.

Leucine → mTORC1 → muscle protein synthesis. The central mechanism: leucine arriving at skeletal muscle (above the ~2.5 to 3.0 g per-meal threshold) binds Sestrin2 and disinhibits the mTORC1 complex, which then phosphorylates p70S6K and 4E-BP1 to initiate translation. Whey delivers ~11% leucine by mass — the highest of any common protein source — which is why a 25 to 30 g whey serving (yielding ~2.7 to 3.3 g leucine) reliably triggers MPS. See /ingredients/whey-protein/#mechanism and /ingredients/protein/#per-meal.

Endogenous GLP-1 / GIP release via whey. Whey is among the strongest endogenous GLP-1 / GIP releasers per gram (Jakubowicz 2014 PMID 25005331). This is relevant for athletic performance via the satiety and metabolic-flexibility angle, and especially relevant for the GLP-1 Companion page.

Mitochondrial antioxidant capacity via astaxanthin. Astaxanthin's xanthophyll structure engages mitochondrial-membrane antioxidant capacity. In the exercise context, the Liu 2024 meta-analysis (PMID 38243785) supports the fatigue and motor-function endpoint; specific exercise performance trials are mixed (Brown 2021 cycling crossover PMID 32660833 reported partial signals; Gonzalez 2024 firefighter crossover PMID 39568140 reported non-significant fasting outcomes other than ventilatory anaerobic threshold).

Yeast protein — amino-acid spectrum approaches animal-protein profile. Saccharomyces cerevisiae-derived protein, in current preparations, has a DIAAS estimate of 0.82 to 1.00 (Cao 2024 PMID 39303477; Qiao 2025 PMID 40934397, INFOGEST in-vitro). Direct human MPS-endpoint RCT in yeast protein remains sparse — Layer 1 (direct yeast-protein evidence) is currently limited to in-vitro and rat data plus one 8-week human trial published in a non-PubMed-indexed journal; Layer 2 cites mycoprotein analogy (PMID 32438401 Monteyne 2020); Layer 3 cites yeast β-glucan literature (PMID 33900466 Zhong 2021) with the explicit caveat that β-glucan is a separate molecule, not a protein.

Creatine + disuse-recovery mechanism — older-adult-relevant. The Hespel 2001 J Physiol RCT (PMID 11600695) immobilized a single leg of healthy adults for 2 weeks and showed that oral creatine supplementation during the immobilization and the subsequent 10-week rehabilitation training accelerated muscle-fibre cross-sectional area recovery and altered the expression of muscle myogenic regulatory factors (MyoD, Myf5, Myogenin, MRF4) — a mechanism directly relevant to seniors recovering from injury, surgery, or hospitalization-related bed rest. This is a disuse-recovery signal, distinct from the better-known acute high-intensity ergogenic effect.

β-Alanine + carnosine + intracellular pH buffering. Trexler 2015 ISSN position stand (PMID 26175657) frames the mechanism: oral β-alanine elevates skeletal-muscle carnosine over ~4 weeks at 4 to 6 g/day, and carnosine functions as the dominant intracellular pH buffer in fast-twitch muscle. The performance signal is most pronounced in exercise lasting ~1 to 4 minutes (where lactic-acidosis-driven fatigue is the limiting factor) — not in single-rep maximal strength and not in pure endurance events lasting hours. Paraesthesia is the only commonly-reported side effect.

Protein-adequate diet first, supplements second. The Cermak 2012 meta-analysis (PMID 23134885) of 22 RCTs (n=680, both younger and older adults) is the foundational signal for protein supplementation as adjunct to resistance training — but as Cintineo 2018 review (PMID 30255023, Front Nutr) emphasizes, when total dietary protein intake meets ~1.6 g/kg/day from whole-protein sources, the marginal anabolic gain from additional supplemental protein narrows. Supplementation is most defensible when dietary intake falls short of the threshold, or for practical adherence convenience around training windows.

Body systems engaged: Musculoskeletal · Mitochondrial & Cellular Energy. Mechanism tags: mTOR regulation · Protein synthesis / mTOR coordination · Free radical scavenging.

What the Trials Show — Including the Nulls

The "ergogenic supplement" category is overstated in marketing. Outside of caffeine, creatine (broadly well-established in the wider sports-nutrition literature), and whole-protein adequacy, the evidence for additional ergogenic supplements (BCAA, beta-alanine, citrulline, beetroot, etc.) is more population-, dose-, and modality-specific than blanket claims suggest. The related-ingredients list reflects the ingredients currently evidence-curated here, not the full sports-nutrition supplement universe.

Marginal benefit of supplementation on protein-adequate diet. When daily protein intake from whole-protein sources already meets the Morton 2018 (PMID 28698222) ~1.6 g/kg/day threshold, the marginal benefit of adding protein, BCAA, or amino-acid supplements is small. Cermak 2012 (PMID 23134885) shows protein supplementation augments resistance-training response in meta-analytic pooled data, but the effect size is conditional on baseline dietary adequacy. Cintineo 2018 (PMID 30255023, Front Nutr) frames supplementation primarily as an adherence and timing-convenience tool, not as a foundational anabolic lever above whole-food dietary patterns. The transparent read: supplements are the marginal lever; whole-food protein adequacy plus resistance training is the foundational lever.

Creatine and BCAA. Do not assume the popular sports-nutrition positioning of creatine (broad ergogenic dominance) or BCAA (standalone anabolic) maps directly to high-quality meta-analytic evidence. The single Hespel 2001 (PMID 11600695) creatine citation is included as the named disuse-recovery trial context, not as a generalized ergogenic claim.

Stacking & Timeline

Mechanistic pairings are plausible but rarely backed by head-to-head synergy trials; the strongest "synergy" in athletic-protein practice is a per-meal distribution pattern, and realistic timelines run from hours (acute MPS) to months (chronic lean-mass divergence).

Mechanistic pairs

Whey + whole-protein dietary framework · the per-meal pattern. The strongest "synergy" in athletic-protein practice is not a multi-ingredient combination but rather a per-meal distribution pattern: 25 to 30 g of high-quality protein per meal (yielding ~2.7 to 3.3 g leucine per meal) at 4 meals per day to support whole-body resistance training (Macnaughton 2016 PMID 27511985 — 40 g whey produced greater MPS than 20 g whey after whole-body sessions).

Astaxanthin + training adaptation · recovery-axis pair (mechanism). The Liu 2024 meta-analysis fatigue and motor function signal pairs mechanistically with mitochondrial-antioxidant capacity during recovery from training stress. Head-to-head clinical synergy with whole-protein adequacy is not established as a separate trial design.

Creatine + Whey · classic ergogenic + structural pair (mechanism). Broadly well-established in the sports-nutrition literature. The Hespel 2001 (PMID 11600695) disuse-recovery mechanism is the older-adult cross-system anchor — relevant when rehab from injury or hospitalization-related muscle disuse is the context.

β-Alanine + creatine · independent-mechanism stacking (cross-reference). β-Alanine acts via muscle-carnosine intracellular pH buffering (Trexler 2015 ISSN PMID 26175657); creatine acts via phosphocreatine ATP-resynthesis kinetics. The mechanisms are independent, so stacking is mechanistically defensible — but neither replaces the protein + resistance-training foundation.

Protein + Resistance Training · the structural foundation pair (Cermak 2012). Cermak 2012 meta (PMID 23134885) — protein supplementation augments the adaptive response to resistance training across 22 RCTs in both younger and older adults. Cintineo 2018 (PMID 30255023, Front Nutr) extends the framing to recovery in endurance contexts as well. This is the most evidence-supported pair on this page; all supplemental ergogenic aids are layered on top of, not in place of, this structural pair.

When to see results — realistic timeframes

Acute (single meal) · MPS spike. Per-meal protein at the leucine threshold triggers MPS within hours (Tang 2009 PMID 19589961). This is acute biochemistry, not chronic outcome.

8 to 12 weeks · strength and lean-mass gain. Morton 2018 (PMID 28698222) pooled trials averaged 13 weeks; the modal trial reported significant lean-mass and strength gain by week 12 when protein adequacy meets ~1.6 g/kg/day and resistance training is the stimulus.

9 months · whey vs soy chronic head-to-head divergence. Volek 2013 (PMID 24015719) reported +3.3 kg lean mass on whey vs +1.8 kg on soy vs +2.3 kg on maltodextrin over 9 months — the chronic gap is real but smaller than the acute gap suggests.

12 weeks · astaxanthin fatigue and motor function signal. The Liu 2024 meta-analysis (PMID 38243785) pooled trials typically at 6 to 24 mg/day for 8 to 12 weeks.

4 weeks · β-alanine muscle-carnosine elevation and performance gain. The Trexler 2015 ISSN position stand (PMID 26175657) is explicit: 4 to 6 g/day for a minimum of 4 weeks is required to meaningfully elevate skeletal-muscle carnosine and translate to performance gain in 1- to 4-minute high-intensity exercise. Shorter durations do not yield consistent benefit.

10 to 12 weeks · disuse-recovery on creatine. The Hespel 2001 J Physiol RCT (PMID 11600695) protocol used 2 weeks of leg immobilization followed by 10 weeks of rehabilitation training; the creatine-group muscle-CSA recovery advantage emerged across this rehabilitation window. Relevant for seniors recovering from post-surgical immobilization or hospitalization-related bed rest.

  • GLP-1 Companion — whey GLP-1 / GIP release (Jakubowicz 2014 PMID 25005331) and muscle-preservation logic overlap directly.
  • Weight Management — Baer 2011 (PMID 21677076) free-living whey body-composition signal; protein during energy restriction logic.
  • Longevity Stack — NMN-vs-NAD+ pathway overlap with athletic-endpoint trials (Liao 2021 PMID 34238308 amateur runners; Igarashi 2022 PMID 35927255 older men).
  • Senior 60+ — sarcopenia-prevention protein-adequacy logic and the PROVIDE trial (Bauer 2015 PMID 26170041).

Frequently Asked Questions

1. How much protein do I really need to gain muscle?

For strength athletes, 1.6 to 2.2 g/kg/day is the evidence-supported range; the 1.6 g/kg/day threshold from Morton 2018 (PMID 28698222) is where the marginal MPS gain plateaus. Higher intakes are not harmful in healthy adults but are not more anabolic.

2. Is whey actually better than plant protein?

Acutely, yes — whey produces higher per-meal MPS response than soy or casein, driven by the highest leucine content (~11%) and fastest digestion (Tang 2009 PMID 19589961). Chronically over 9 months, whey still beats soy on lean mass (Volek 2013 PMID 24015719, +3.3 vs +1.8 kg), but the gap is smaller than the acute trial suggests. When total daily intake meets 1.6 to 2.2 g/kg/day, well-formulated DIAAS-matched plant blends close most of the gap.

3. What is the deal with yeast protein?

Yeast protein (Saccharomyces cerevisiae-derived) has transparent layered evidence. Layer 1 (direct yeast-protein evidence) is currently small — Cao 2024 PDCAAS in-vitro (PMID 39303477), Qiao 2025 INFOGEST (PMID 40934397), Van den Abbeele 2026 ex-vivo gut barrier (PMID 41568030), plus one 8-week human trial in a journal not indexed by PubMed. Layer 2 cites mycoprotein analogy (PMID 32438401). Layer 3 cites yeast β-glucan immune literature with the explicit caveat that β-glucan is a separate molecule. The honest read: yeast protein is amino-acid-spectrum-equivalent to common proteins, but the human muscle-endpoint RCT base is still building.

4. Should I take BCAAs?

If total protein intake meets 1.6 to 2.2 g/kg/day from whole-protein sources, supplemental BCAAs add little. Leucine triggers mTOR, but the other essential amino acids are needed as substrate.

5. Does creatine work?

Broadly, creatine is the most evidence-backed ergogenic supplement in the sports-nutrition literature for strength, high-intensity output, and lean-mass support. One older-adult-relevant signal is the Hespel 2001 J Physiol RCT (PMID 11600695): oral creatine during a 2-week leg-immobilization period followed by 10-week rehab training accelerated muscle-fibre cross-sectional area recovery — relevant for post-surgical or hospitalization-related disuse contexts. Reasonable usage in the broader literature is 3 to 5 g/day creatine monohydrate.

6. Does astaxanthin improve endurance?

The Liu 2024 meta-analysis (PMID 38243785) of 11 RCTs supports a fatigue and motor function signal. Specific exercise-performance trials are mixed: Brown 2021 cycling crossover (PMID 32660833) reported partial signals; Gonzalez 2024 firefighter crossover (PMID 39568140) reported non-significant fasting outcomes other than ventilatory anaerobic threshold. The honest framing: meta-analytic fatigue signal is real; specific performance metric outcomes are population- and protocol-dependent.

7. Should I take β-alanine?

β-Alanine has robust ISSN position-stand evidence (Trexler 2015 PMID 26175657) for high-intensity exercise lasting roughly 1 to 4 minutes — the lactic-acidosis-driven fatigue window. Effective dose is 4 to 6 g/day for at least 4 weeks, working through muscle-carnosine elevation and intracellular pH buffering. The most common side-effect is paraesthesia (skin tingling), reduced by divided dosing or sustained-release formulas. β-Alanine is NOT a general "performance enhancer" for all sports — it is most defensible for 800m-to-mile track running, rowing, swimming sprint events, CrossFit-style metabolic-conditioning intervals, and similar 1- to 4-minute high-intensity contexts. Single-rep maximum strength and pure aerobic endurance events are not the target.

8. How important is the protein + resistance training combination vs supplements?

The protein + resistance-training combination is the foundational lever; supplements are the marginal lever. Cermak 2012 meta-analysis (PMID 23134885) of 22 RCTs in both younger and older adults anchors the framing that protein supplementation augments the response to resistance training. Cintineo 2018 review (PMID 30255023, Front Nutr) extends to recovery in resistance + endurance contexts. The transparent read: when daily intake meets Morton 2018's (PMID 28698222) ~1.6 g/kg/day threshold from whole-protein sources and resistance training is the stimulus, supplemental ergogenic aids (BCAA, β-alanine, etc.) add marginal — not foundational — performance benefit. Get the foundation right first.

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

  1. PMID 28698222 · Morton RW et al. (2018) · protein dose-response meta-analysis · 49 RCTs (n=1,863) · ~1.6 g/kg/day threshold for lean-mass plateau
  2. PMID 24284442 · Churchward-Venne 2014 · leucine as the MPS trigger · 25 g whey vs 6.25 g whey + supplemental leucine both stimulate MPS
  3. PMID 19589961 · Tang 2009 · acute MPS head-to-head · whey > soy > casein
  4. PMID 24015719 · Volek 2013 · 9-month chronic whey vs soy · +3.3 kg vs +1.8 kg lean mass (maltodextrin +2.3 kg)
  5. PMID 27511985 · Macnaughton 2016 · 40 g vs 20 g whey after whole-body resistance exercise · greater MPS at 40 g
  6. PMID 21677076 · Baer 2011 · 23-week free-living whey body-composition signal
  7. PMID 39303477 · Cao 2024 · yeast protein INFOGEST + rat study · PDCAAS ~1.00 · DIAAS estimate ~0.82–1.00
  8. PMID 40934397 · Qiao 2025 · yeast protein INFOGEST in-vitro digestibility
  9. PMID 41568030 · Van den Abbeele 2026 · yeast protein ex-vivo gut-microbiota · non-inferior to whey/soy on barrier + SCFA endpoints
  10. PMID 32438401 · Monteyne 2020 · mycoprotein MPS analogy (Layer 2 cross-reference for yeast protein)
  11. PMID 33900466 · Zhong 2021 · yeast β-glucan literature (Layer 3 · separate molecule caveat)
  12. PMID 38243785 · Liu 2024 · astaxanthin fatigue/motor-function meta-analysis · 11 RCTs (n=346) · significant pooled effects
  13. PMID 32660833 · Brown 2021 · astaxanthin cycling crossover RCT · partial signals
  14. PMID 34110707 · Liu 2021 · astaxanthin elderly aerobic RCT
  15. PMID 39568140 · Gonzalez 2024 · astaxanthin firefighter crossover RCT (n=15, 12 mg/day, 4 wk) · oxidative/lipid/tactical outcomes non-significant except ventilatory anaerobic threshold
  16. PMID 11600695 · Hespel 2001 · J Physiol · oral creatine + 2-wk leg immobilization + 10-wk rehab · accelerated muscle-CSA recovery (disuse-recovery signal)
  17. PMID 26175657 · Trexler 2015 · ISSN position stand on β-alanine · 4–6 g/day ≥4 wk increases muscle carnosine · buffers pH for 1–4 min high-intensity exercise
  18. PMID 23134885 · Cermak 2012 · protein + resistance-training meta-analysis · 22 RCTs (n=680, younger + older adults)
  19. PMID 30255023 · Cintineo 2018 · Front Nutr · protein supplementation in resistance + endurance training review
  20. PMID 27807480 · Antonio 2016 · high-protein (up to 3.0 g/kg/day) safety in trained adults for ≤1 year
  21. PMID 25005331 · Jakubowicz 2014 · whey endogenous GLP-1 / GIP release (cross-link context)

Coverage Notes

This Athletic Performance page draws from four linked ingredient pages (yeast-protein, astaxanthin, creatine, BCAA), plus the broader protein and whey-protein references even though they are not in the related-ingredients frontmatter list — this is reasonable because those pages anchor the per-meal MPS framework that the athletic context inherits. Where high-quality direct PMID citations for creatine and BCAA do not yet exist, this page describes their evidence qualitatively as preliminary / emerging in the evidence stack and treats them as mechanism candidates in How It Works, rather than fabricating citations. This page also cross-references four additional verified anchors that strengthen the protein-adequacy + ISSN ergogenic + disuse-recovery framing: Cermak 2012 (PMID 23134885), Cintineo 2018 (PMID 30255023), Hespel 2001 (PMID 11600695), and Trexler 2015 (PMID 26175657) — all four independently four-field verified against PubMed (author, year, title, journal). PMID 24787496 (originally proposed as a Daly RM 2014 outcome-paper anchor) failed four-field verification — that PMID actually indexes Bhupathiraju 2014 on glycemic index and type-2 diabetes risk — so the Daly 2014 anchor was not added; only verified anchors are cited. The page deliberately frames supplements as the marginal lever and protein-adequate diet plus resistance training as the foundational lever, consistent with the transparent-disclosure principle on supplement marginal benefit.

← Home

Ask Agent Axor